Generation Park Emerges as a Major Pharmaceutical Hub in Houston

📅 Today

Generation Park in Houston, Texas, is becoming a focal point for pharmaceutical manufacturing investments, with major commitments from Eli Lilly and Bristol Myers Squibb, supported by local educational initiatives to address workforce needs.

In a significant move for the pharmaceutical sector, Eli Lilly has announced a $6.5 billion investment to establish a new manufacturing facility, while Bristol Myers Squibb (BMS) is contemplating the construction of a 600,000-square-foot facility. Both companies have chosen the expansive Generation Park, which spans 4,300 acres northeast of Houston, Texas, as the site for their upcoming ventures. The appeal of Generation Park can be attributed to several factors, including lower land costs, favorable tax conditions, and the newly launched Texas Jobs, Energy, Technology, and Innovation program, which commenced in January 2024. These incentives are drawing significant interest from major manufacturers across various industries, particularly within pharmaceuticals, aligning with the previous administration's push to re-shore the U.S. drug manufacturing sector.
U.S. Secretary of Commerce Howard Lutnick remarked, "We are making pharmaceuticals in America again thanks to President Trump’s America First Trade Agenda." Zach Leger, vice-president of health care and life sciences at real estate firm JLL, highlighted the strategic advantages of Generation Park, which offers sites specifically deed-restricted for life sciences. The park's advantageous location near both the Port of Houston and George Bush Intercontinental Airport, combined with access to reliable power interconnections, enhances its attractiveness for companies like Eli Lilly and BMS.
Within Generation Park, McCord Development is currently developing BioHub Two, a 45-acre biomanufacturing campus that will feature over a million square feet of available space for biomanufacturing, laboratories, and offices tailored for life sciences companies. This development is part of a broader vision by Ryan McCord, CEO of McCord Development, who recognized Houston's potential as a leader in life sciences, despite seeing investments in biotech shift to other cities in recent years.
One of the primary challenges for the Houston area has been a shortage of skilled technicians necessary for laboratory operations and research functions. In response, McCord has collaborated with San Jacinto College to establish a Center for Biotechnology, which aims to bridge this skills gap. McCord stated, "San Jacinto College’s Biotechnology Center at Generation Park is the catalyst our region needs to fill the gap in our existing life science ecosystem and accelerate biomanufacturing in Houston." The center is equipped to provide training for pharmaceutical manufacturing roles, with graduates expected to find employment opportunities with the new companies setting up operations in the park and throughout Texas.
Shaun Noorian, CEO of Empower Pharmacy, a substantial compounding pharmacy based in Houston, expressed enthusiasm about the Biotechnology Center, noting its importance for the local biopharmaceutical sector. He emphasized that prior to the center’s establishment, companies had to develop their own training programs. "The Center for Biotechnology is going to add a lot of value not just to our company but to all the other biopharmaceutical companies that want to create sites here," Noorian explained.
In addition to Eli Lilly and BMS, United Therapeutics is also planning to develop a specialized facility at Generation Park, encompassing 22 acres and costing $96 million. This facility will focus on breeding genetically modified swine for human organ transplantation. Generation Park is also home to the Process Technology Center of Lone Star College and various companies from other sectors, including energy services firm TechnipFMC and Apache Industrial Services, which specializes in industrial and commercial service provision.
The recent multi-billion dollar investments from pharmaceutical giants have generated significant excitement in the region. Eli Lilly's filing in July with the Texas Department of Licensing and Regulation indicated that construction on various facilities was expected to commence within the following months. The completion of the entire 236-acre campus is anticipated by 2030, with CRB Architects PC and Jacobs Engineering Group engaged for the design work. Eli Lilly has secured property tax exemptions from the local school district, along with various state incentives, and anticipates creating 615 high-wage jobs, including roles for engineers, scientists, operations staff, and lab technicians, while generating around 4,000 construction jobs during the build phase.
In early August, BMS confirmed its selection of Generation Park for a $2.3 billion multi-modal manufacturing campus, supported by a state grant of $4.89 million. The facility is expected to create nearly 500 skilled jobs. BMS stated that this decision is part of its broader $40 billion investment strategy in the U.S. over five years, focusing on research, technology, and domestic manufacturing. The design of the BMS campus is modular, allowing for future adaptability in manufacturing capacity, and it will support the production of various types of medicines across multiple disease areas. Governor Greg Abbott remarked, "Texas is the best state in America for doing business," underscoring the state’s efforts to enhance manufacturing capabilities within the biomedical sector.

Related Posts